Clinical Trial Update: Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion [Phase 4]

View source ↗

Summary

Phase 4 trial comparing extended-infusion piperacillin-tazobactam to intermittent infusion for Gram-negative infections has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gram-negative Infections

Drugs mentioned

• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Ain Shams University | Conditions: Gram-Negative Infections | Phase 4 | Status: COMPLETED